Your session is about to expire
← Back to Search
Virus Therapy
Bacteriophage Therapy in Patients With Urinary Tract Infections
Phase 1 & 2
Waitlist Available
Led By Robert J Hopkins, MD
Research Sponsored by Adaptive Phage Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a treatment that uses viruses to kill bacteria in patients with urinary tract infections. It focuses on people with infections caused by E. coli and K. pneumoniae, including those with recurring or complicated cases. The goal is to see if this treatment can safely and effectively clear the infection. Bacteriophage therapy has shown potential as an effective and safe treatment for urinary tract infections, but there is a lack of comprehensive studies.
Eligible Conditions
- UTI
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Identify ideal bacteriophage treatment regimens based on improvements in disease control rates
Secondary study objectives
Phage Therapy
Assess the tolerability of bacteriophage therapy
Other study objectives
Recurrence of urinary tract infection
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
6Treatment groups
Experimental Treatment
Group I: Subcohort DExperimental Treatment1 Intervention
Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
Group II: Subcohort CExperimental Treatment1 Intervention
Selected phage for E. coli administered via selected route based on previous Arms.
Group III: Subcohort BExperimental Treatment1 Intervention
Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
Group IV: Subcohort AExperimental Treatment1 Intervention
Selected phage for E. coli administered via selected route based on previous Arms.
Group V: Intravesical (IVS)Experimental Treatment1 Intervention
Phage administered via the intravesical route.
Group VI: Intravenous (IV)Experimental Treatment1 Intervention
Phage administered via the intravenous route.
Find a Location
Who is running the clinical trial?
Adaptive Phage Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
126 Total Patients Enrolled
United States Department of DefenseFED
913 Previous Clinical Trials
334,305 Total Patients Enrolled
Robert J Hopkins, MDPrincipal InvestigatorChief Medical Officer
1 Previous Clinical Trials